Accessibility Menu
Pyxis Oncology logo

Pyxis Oncology(NASDAQ) PYXS

Market Cap$181.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-78%
5 YearN/A
1 Year+137%
1 Month-7%
$2.65
-7.67%
-0.22Today
After hours$2.65-$0.01 (-0.19%)
Pyxis Oncology last closing stock price
MetricPriceDate
Last closeUSD 2.652026-07-31
Pyxis Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.53%USD 2.612026-07-24
1 month-7.02%USD 2.852026-07-01
3 month+54.07%USD 1.722026-05-01
Year to date+130.43%USD 1.152025-12-31
1 year+136.61%USD 1.122025-07-31
3 year+3.11%USD 2.572023-08-01
Since inception-78.26%USD 13.202021-10-08

Pyxis Oncology Financials at a Glance

Market Cap

$181.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$13.86M

Net Income (TTM)

-$81.74M

EPS (TTM)

-$1.30

P/E Ratio

-2.20

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$2.65

Volume

750,108.333

Open

$2.84

Previous Close

$2.65

Daily Range

$2.63 - $2.85

52-Week Range

$0.97 - $5.55

Estimated Earnings Date

Aug 13, 2026

PYXS News

No articles available.

PYXS: Motley Fool Moneyball Superscore

41

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pyxis Oncology

Pyxis Oncology develops new medicines for people with cancer. Its main products aim to help patients whose tumors do not respond to standard treatments. The company focuses on therapies that target cancer cells while sparing healthy tissue.

Products and Services

  • MICVO (micvotabart pelidotin): Investigational antibody-drug conjugate for head and neck cancer and other solid tumors; 0% of product sales revenue, but 100% of clinical focus.
  • PYX-106: Antibody therapy for solid tumors; clinical development paused in 2025.
  • PYX-102: Immune therapy for solid tumors; early-stage development.
  • PYX-203: Antibody-drug conjugate for blood cancers; early-stage development.
  • Licensing and Royalty Agreements: Revenue from out-licensed programs, including milestone payments and royalty rights sales; 100% of 2025 revenue.

Growth and Expansion

  • Acquired the APXiMAB antibody discovery platform from Apexigen in 2023.
  • Licensed the FACT antibody-drug conjugate platform from Pfizer in 2021.
  • Entered clinical trial collaboration with Merck for MICVO and pembrolizumab in 2025.
  • Expanded global clinical trial sites for MICVO in 2025.
  • Out-licensed royalty rights to Simcere in China, generating milestone and royalty revenue starting in 2025.

What Makes Pyxis Oncology Stand Out

Pyxis Oncology targets proteins found mostly in tumors, aiming for precise drug delivery. Its main drug candidate uses a three-part approach to attack cancer cells. The company relies on partnerships and licensed technology to advance its pipeline.

Five Things You Need to Know

  • All 2025 revenue came from licensing and royalty rights, not product sales.
  • Net loss was $79.6 million in 2025, up 3% from 2024.
  • Cash position was $66.9 million at December 31, 2025, down approximately 49% year-over-year.
  • Research and development spending rose approximately 25.6% to $73.7 million in 2025.
  • Company expects current cash to last into Q4 2026, with no debt outstanding.

Bottom Line

Pyxis Oncology remains focused on developing targeted cancer therapies and relies on licensing for revenue. The company faces ongoing losses but continues to invest in research and clinical trials.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

56

CEO

Thomas Civik, MBA

Website

www.pyxisoncology.com

Headquarters

Boston, MA 02140, US

PYXS Financials

Key Financial Metrics (TTM)

Gross Margin

99.81%

Operating Margin

-619.61%

Net Income Margin

-589.80%

Return on Equity

-135.60%

Return on Capital

-117.12%

Return on Assets

-127.12%

Earnings Yield

-45.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$181.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

63.36M

Volume

750.11K

Avg. Volume

975.80K

Financials (TTM)

Gross Profit

$13.83M

Operating Income

-$85.87M

EBITDA

-$75.93M

Operating Cash Flow

-$66.97M

Capital Expenditure

-$9.00K

Free Cash Flow

-$66.98M

Cash & ST Invst.

$42.49M

Total Debt

$18.26M

Pyxis Oncology Performance Analysis

Pyxis Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 16,146,000N/A
20252025-12-31USD 13,858,000-14.2%
Pyxis Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31-100.0%
Pyxis Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.6555.0%
20232023-12-31USD -1.85-49.4%
20242024-12-31USD -1.32-28.5%
20252025-12-31USD -1.28-3.2%
Pyxis Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3014.3%
Q32025-09-30-16.7%
Q42025-12-3117.1%
Q12026-03-31-27.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$459.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$181.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.25M

N/A

Employees

56

N/A

Net Income

-$23.27M

-10.0%

EBITDA

-$22.81M

-10.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$42.49M

-59.7%

Total Debt

$18.26M

-8.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$16.50M

-10.0%

Short Term Debt

$1.76M

+16.5%

Return on Assets

-1.27%

N/A

Return on Invested Capital

-1.80%

N/A

Free Cash Flow

-$26.00M

-15.4%

Operating Cash Flow

-$26.00M

-15.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VYGRVoyager Therapeutics, Inc.
$3.03-3.19%
TNYATenaya Therapeutics, Inc.
$0.74-1.29%
IMRXImmuneering Corporation
$4.13-2.36%
CRBUCaribou Biosciences, Inc.
$1.46-3.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About PYXS

What is the current price of Pyxis Oncology?

Pyxis Oncology is trading at $2.65 per share.

What is the 52-week range for Pyxis Oncology?

Over the past 52 weeks, Pyxis Oncology has traded between $0.97 and $5.55.

How much debt does Pyxis Oncology have?

As of the most recent reporting period, Pyxis Oncology reported total debt of $18.26M.

How much cash does Pyxis Oncology have on hand?

Pyxis Oncology reported $7.24M in cash and cash equivalents in its most recent financial results.

What is Pyxis Oncology’s dividend yield?

Pyxis Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services